LQDA vs TRVI
LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension. TRVI: Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated with severe lung diseases like IPF.
Side-by-side fundamentals
| Metric | LQDA | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $89.42 | $18.50 | |
| Market cap as of 2026-08-08 | $8.0B | $2.6B | |
| P/E as of 2026-08-08 | 359.70 | n/a | |
| Net margin as of 2026-08-08 | +7.7% | n/a | |
| Gross margin as of 2026-08-08 | +91.8% | n/a | |
| Operating margin as of 2026-08-08 | +15.8% | n/a | |
| ROE as of 2026-08-08 | +46.8% | -24.5% | LQDA higher |
| ROA as of 2026-08-08 | +7.1% | -23.4% | LQDA higher |
| Debt / equity as of 2026-08-08 | 1.64 | 0.00 | TRVI lower |
| Revenue CAGR (3y) SEC XBRL | +115.0% | n/a | |
| Beta as of 2026-08-08 | 0.57 | 0.92 | |
| 1-year return as of 2026-08-06 close | +340.3% | +154.5% | LQDA higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.